Flag Ship Acquisition (NASDAQ:ETHZ) Trading 2.1% Higher – Here’s Why
by Michael Walen · The Markets DailyShares of Flag Ship Acquisition Corp. (NASDAQ:ETHZ – Get Free Report) traded up 2.1% on Thursday . The company traded as high as $4.96 and last traded at $4.87. 443,778 shares were traded during mid-day trading, a decline of 93% from the average session volume of 6,436,919 shares. The stock had previously closed at $4.77.
Flag Ship Acquisition Stock Performance
The company has a debt-to-equity ratio of 1.11, a quick ratio of 10.07 and a current ratio of 10.07. The stock’s fifty day moving average is $3.83 and its two-hundred day moving average is $5.01. The firm has a market cap of $96.77 million, a price-to-earnings ratio of -0.03 and a beta of 1.17.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Flag Ship Acquisition stock. DRW Securities LLC purchased a new stake in shares of Flag Ship Acquisition Corp. (NASDAQ:ETHZ – Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 270,733 shares of the company’s stock, valued at approximately $1,327,000. DRW Securities LLC owned 1.42% of Flag Ship Acquisition as of its most recent filing with the Securities and Exchange Commission (SEC). 4.07% of the stock is currently owned by institutional investors and hedge funds.
About Flag Ship Acquisition
1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor.